-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: January 2010
Fewer Public Biotechs in 2010 vs 2008
Back in January 2008, we were tracking 394 “active” public biotech companies. (By “active”, we mean companies that are filing with the SEC and not in bankruptcy or in a major restructuring due financial distress.) As of January 2010, we have 295 – a loss of ~25%. About 48% of the companies that are no longer “active” have been acquired and 52% have gone out of business, filed bankruptcy, or are no longer filing with Read More >
Weekly Blog Round Up
Biofuels are big in Iowa. So big in fact, that according to domesticfuel.com “Iowa State University will get $8 million of a $78 million U.S. Department of Energy grant to research and develop advanced biofuels.” “These Iowa State research projects are paid for by stimulus bucks … the same money that is funding the $44 million to the Donald Danforth Plant Science Center in St. Louis, Mo. (…..) and the $34 million (plus $8.4 million Read More >
BIO Asia partnering is heating up!
Less than a week to go until the 7th Annual BIO Asia International Partnering Conference and it is clear that we are on pace to beat the number of total partnering meetings done from last year. Check out the little snippet from Google analytics to the right. This past Monday represented the highest day of activity within the system to date! In 2008, we had a total of 693 partnering meetings scheduled at the conference Read More >
The Evolution of BIO Partnering
I joined BIO in the summer of 2008, just as the global biotechnology community headed towards sunny San Diego. This was my first experience with the scale of partnering that occurs at that meeting. Constantly trying to be on the forefront of innovation, the BIO BD team has put forth an increased effort into converting their partnering software form a utilitarian piece of software into something that is much more. The last 18 months have Read More >
IP Professors: 12-Year Data Exclusivity a Win-Win for Patient Access & Biotech Innovation
David E. Adelman of the University of Texas School of Law and Christopher M. Holman of the University of Missouri – Kansas City School of Law recently published analysis on the “sideshow” of the data exclusivity debate in Washington.
Adelman and Holman use a cost-benefit analysis that incorporates the most important legal precedents and case law today in concluding that “policymakers should focus on mitigating the systematic barriers to entry that pose much greater and longer-term obstacles to lower-cost biotech drugs.” Specifically, the draft paper provides solid analysis of the need for 12-year data exclusivity, which the authors describe as a perfect balance between providing access to important medicines to patients, and creating the incentives needed for investors and companies to prepare (and survive) the regulatory approval process for follow-on biologics.
